|
1. Biologie
|
|
|
|
|
3.1.1 Prévention - Tabac - e-cigs
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
4.7 Dép., diag. & prono. - Col de l'utérus
|
|
|
FDA Approves Roche HPV Test for SurePath Collection Media [Genome Web]
|
|
|
|
|
|
Becton
Dickinson's SurePath preservative fluid is commonly used as a
collection medium for Pap tests. The Cobas test is now approved for use
as a primary screening test with SurePath and Hologic's ThinPrep
PreservCyt Solution, the two liquid media used to collect samples for
the vast majority of Pap or HPV tests in the US, Roche said.
|
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
New drugs and new ideas are transforming AML [The Cancer Letter]
|
|
|
|
|
|
In
this issue, The Cancer Letter presents a case study in AML that
examines change as it occurs—focusing on the roles of FDA, The Leukemia
& Lymphoma Society, industry, and academic oncologists have played
in developing new therapies. Since last April, FDA has approved five
agents for the treatment of front-line and relapsed AML, with the most
recent of these approvals announced last week.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
Lilly firms up cancer collaboration with Dana-Farber [FierceBiotech]
|
|
|
|
|
|
The
relationship has already seen some staff movement between the two
organizations, with Dana-Farber cancer genomics expert Levi Garraway,
M.D., Ph.D., taking over the role of senior vice president of global
development and medical affairs for oncology at Lilly in 2016.
|
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
FDA outlines a laundry list of surrogate endpoints with an eye to expanding the roster for drug developers [EndPoints]
|
|
|
|
|
|
The
list, which will be updated every six months, features surrogate
endpoints for numerous diseases including acromegaly, different cancers,
chronic kidney disease, cystic fibrosis, hepatitis A, B and C, HIV,
hypertension and osteoporosis, among others.
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
FDA approves cancer radiation drug Azedra, sending Progenics stock north [EndPoints]
|
|
|
|
|
|
Azedra
is a new version of the radiopharmaceutical iobenguane I-131. It’s made
using a system known as UltraTrace, which results in less
non-radioactive iobenguane during enrichment leading to greater delivery
of radiation to the tumor. The UltraTrace technology was developed by
Molecular Insight Pharmaceuticals, which was acquired by Progenics in
early 2013.
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.8 Communication
|
|
|
|
|
6.9 Controverses
|
|
|
Richard Smith: Measuring research impact—all the rage but hard to get right [BMJ Blogs]
|
|
|
|
|
|
But
how can research impact be measured? In contrast to measuring numbers
of publications and citations, which is easy and can be automated,
measuring impact (whatever it might be) is hard. Trish Greenhalgh,
professor of primary care in Oxford, has identified 21 different methods
but said that they boiled down into three broad categories; economic,
methods used by social scientists, and methods used by business schools.
|
|
|
|
|
|